CONTACT US
Home > Inhibitors/Agonists> > F 522
25134-54-7-F 522 F 522

F 522

For research use only. Not for therapeutic Use.

  • CAT Number: I027228
  • CAS Number: 25134-54-7
  • Molecular Formula: C10H19NO2
  • Molecular Weight: 185.27
  • Purity: 98%
Inquiry Now
Related Small Molecules: Osocimab     JNJ-18038683     GSK-3/CDK5/CDK2-IN-1    

F 522 is also kown as DA-3031. DA-3031 is a newly developed pegylated filgrastim, a recombinant human granulocyte colony-stimulating factor, that is expected to have an extended duration of action compared with non-modified filgrastim. was developed for prophylactic use in breast cancer.


Catalog Number I027228
CAS Number 25134-54-7
Synonyms

F 522; DA 1701; DA 3023; DA 3031;F522; F-522; Sumiepoch F 522;

Molecular Formula C10H19NO2
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name 2-(dimethylamino)ethyl methacrylate compound with ethene (1:1)
InChI InChI=1S/C8H15NO2.C2H4/c1-7(2)8(10)11-6-5-9(3)4;1-2/h1,5-6H2,2-4H3;1-2H2
InChIKey PNMYDOBPCBCQIA-UHFFFAOYSA-N
SMILES C(C(=C)C)(=O)OCCN(C)C.C=C
Reference

1: Ahn LY, Shin KH, Lim KS, Kim TE, Jeon H, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS. Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects. Clin Drug Investig. 2013 Nov;33(11):817-24. PubMed PMID: 24078278.
2: Park KH, Sohn JH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Hong DS, Park S, Shin SH, Kwon HC, Seo JH. A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer. Invest New Drugs. 2013 Oct;31(5):1300-6. doi: 10.1007/s10637-013-9973-4. Epub 2013 May 16. PubMed PMID: 23677653.
3: Wadhwa M, Bird C, Dougall T, Rigsby P, Bristow A, Thorpe R; participants of the study. Establishment of the first international standard for PEGylated granulocyte colony stimulating factor (PEG-G-CSF): report of an international collaborative study. J Immunol Methods. 2015 Jan;416:17-28. doi: 10.1016/j.jim.2014.10.005. Epub 2014 Oct 25. PubMed PMID: 25450254; PubMed Central PMCID: PMC4334095.
4: Park KH, Lee S, Park JH, Kang SY, Kim HY, Park IH, Park YH, Im YH, Lee HJ, Park S, Lee SI, Jung KH, Kim YS, Seo JH. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer. Support Care Cancer. 2017 Feb;25(2):505-511. doi: 10.1007/s00520-016-3429-2. Epub 2016 Oct 6. PubMed PMID: 27709313.
5: Kam G, Yiu R, Loh Y, Ang AL, Yueh LL, Goh YT, Wong GC. Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy. Support Care Cancer. 2015 Mar;23(3):643-9. doi: 10.1007/s00520-014-2417-7. Epub 2014 Aug 27. PubMed PMID: 25160495.
6: Haller MJ, Gitelman SE, Gottlieb PA, Michels AW, Rosenthal SM, Shuster JJ, Zou B, Brusko TM, Hulme MA, Wasserfall CH, Mathews CE, Atkinson MA, Schatz DA. Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes. J Clin Invest. 2015 Jan;125(1):448-55. doi: 10.1172/JCI78492. Epub 2014 Dec 15. PubMed PMID: 25500887; PubMed Central PMCID: PMC4382237.
7: Skyler JS. Immune therapy for treating type 1 diabetes: challenging existing paradigms. J Clin Invest. 2015 Jan;125(1):94-6. doi: 10.1172/JCI79190. Epub 2014 Dec 15. PubMed PMID: 25500880; PubMed Central PMCID: PMC4382231.
8: Zeynalova S, Ziepert M, Scholz M, Schirm S, Zwick C, Pfreundschuh M, Loeffler M; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Comparison and modelling of pegylated or unpegylated G-CSF schedules in CHOP-14 regimen of elderly patients with aggressive B-cell lymphoma. Ann Hematol. 2013 Dec;92(12):1641-52. doi: 10.1007/s00277-013-1842-x. Epub 2013 Jul 28. PubMed PMID: 23892922.
9: Kang JS, Lee KC. In vivo pharmacokinetics and pharmacodynamics of positional isomers of mono-PEGylated recombinant human granulocyte colony stimulating factor in rats. Biol Pharm Bull. 2013;36(7):1146-51. PubMed PMID: 23811564.
10: Plett PA, Chua HL, Sampson CH, Katz BP, Fam CM, Anderson LJ, Cox GN, Orschell CM. PEGylated G-CSF (BBT-015), GM-CSF (BBT-007), and IL-11 (BBT-059) analogs enhance survival and hematopoietic cell recovery in a mouse model of the hematopoietic syndrome of the acute radiation syndrome. Health Phys. 2014 Jan;106(1):7-20. doi: 10.1097/HP.0b013e3182a4dd4e. PubMed PMID: 24276546; PubMed Central PMCID: PMC3843149.

Request a Quote